Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 5:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 75 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: NR Clear all
Completed Phase 2 Interventional Results available

BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia

NCT01711632
View directory record Official record
Conditions
Hairy Cell Leukemia
Interventions
Vemurafenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2024
U.S. locations
5
States / cities
La Jolla, California • Evanston, Illinois • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 20, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

Multicenter Study Evaluating Certolizumab Pegol Compared to Placebo in Subjects With axSpA Without X-ray Evidence of AS

NCT02552212
View directory record Official record
Conditions
Axial Spondyloarthritis, Nonradiographic Axial Spondyloarthritis, Nr-axSpA
Interventions
Certolizumab Pegol, Placebo
Biological · Other
Lead sponsor
UCB BIOSCIENCES GmbH
Industry
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
36
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Tucson, Arizona + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2022 · Synced Oct 20, 2026, 5:38 PM EDT
Terminated Phase 2 Interventional Results available

NR in Chemo-induced Peripheral Neuropathy

NCT03642990
View directory record Official record
Conditions
Chemotherapy-induced Peripheral Neuropathy, Breast Cancer Metastatic, Platinum-resistant Recurrent Ovarian Cancer, Head and Neck Cancer Stage IV, Endometrial Cancer Stage IV
Interventions
Nicotinamide Riboside
Drug
Lead sponsor
Donna Hammond, PhD
Other
Eligibility
18 Years to 85 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
2
States / cities
Iowa City, Iowa • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Validation of NAD+ Measurements for Human Clinical Studies

NCT07416786
View directory record Official record
Conditions
Healthy Adults
Interventions
Oral NR Supplementation
Dietary Supplement
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 110 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2028
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Early Phase 1 Interventional

Effects of Nicotinamide Riboside on Bioenergetics and Oxidative Stress in Mild Cognitive Impairment/Alzheimer's Dementia

NCT04430517
View directory record Official record
Conditions
Mild Cognitive Impairment, Mild Alzheimer Disease
Interventions
Nicotinamide riboside
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 89 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Phase 1 Interventional

Nicotinamide Riboside (NR) to Treat Moyamoya-like Cerebrovascular Disease in Smooth Muscle Dysfunction Syndrome (SMDS)

NCT06280482
View directory record Official record
Conditions
Smooth Muscle Dysfunction Syndrome (SMDS)
Interventions
Nicotinamide riboside (NR)
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
1 Year and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Pharmacokinetics, Pharmacodynamics and Safety of Basis in Acute Kidney Injury Study

NCT03176628
View directory record Official record
Conditions
Acute Kidney Injury
Interventions
Basis, Placebo
Dietary Supplement
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 27, 2019 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 4 Interventional Results available

Etanercept Withdrawal And Retreament Study In Subjects With Nr-ax SpA

NCT02509026
View directory record Official record
Conditions
Spondylitis, Ankylosing
Interventions
Etanercept
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
12
States / cities
Pensacola, Florida • Chicago, Illinois • Mineola, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Protection From Acute Kidney Injury (AKI) With Basis™ Treatment

NCT04342975
View directory record Official record
Conditions
AKI
Interventions
Nicotinamide Riboside + Pterostilbene, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Early Phase 1 Interventional

Chemoimmunotherapy and Allogeneic Stem Cell Transplant for NK T-cell Leukemia/Lymphoma

NCT03719105
View directory record Official record
Conditions
NK-Cell Lymphoma, NK-Cell Leukemia, Peripheral T Cell Lymphoma
Interventions
Methotrexate, pralatraxate,, Ifosfamide, Dexamethasone, Etoposide, calaspargase pegol, cyclophosphamide, Doxorubicin, Prednisone, Brentuximab Vedotin
Drug
Lead sponsor
New York Medical College
Other
Eligibility
1 Year to 31 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
6
States / cities
Birmingham, Alabama • Orange, California • San Francisco, California + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Study of Affect Induction for Lab Induced Pain in Healthy Undergraduates

NCT05619419
View directory record Official record
Conditions
Meditation, Pain, Mindfulness, Affect, Emotion Regulation
Interventions
Mindfulness-enhanced positive affect induction, Breathing Meditation
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 65 Years
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 22, 2023 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.

NCT06030297
View directory record Official record
Conditions
Peripheral Neuropathy
Interventions
Diode Laser fiber type Selective Stimulator, ZTlido 1.8 % Topical System, PeriCam PSI NR, Medoc Quantitative Sensory Testing, Inactive Topical System
Procedure · Drug · Diagnostic Test + 1 more
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
2
States / cities
Palo Alto, California • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Impacts of Nicotinamide Riboside on Functional Capacity and Muscle Physiology in Older Veterans

NCT04691986
View directory record Official record
Conditions
Sarcopenia, Nicotinamide Adenine Dinucleotide Concentration, Muscle Quality and NAD+ Content
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement · Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
65 Years to 85 Years
Enrollment
74 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Phase 2 Interventional

Exercise Training and NR Supplementation Trial to Improve Fitness in AYA HCT Survivors

NCT05194397
View directory record Official record
Conditions
Lymphoblastic Leukemia, Cancer Survivors, Aplastic Anemia, Myelodysplastic Syndromes, Myeloid Leukemia
Interventions
Nicotinamide Riboside, Placebo, Exercise Intervention
Dietary Supplement · Other
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
10 Years to 30 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
3
States / cities
Duarte, California • Philadelphia, Pennsylvania • Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 4, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 2 Interventional Results available

Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib and/or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

NCT01008150
View directory record Official record
Conditions
Breast Cancer
Interventions
Paclitaxel, Trastuzumab, Neratinib, Doxorubicin, Cyclophosphamide
Drug
Lead sponsor
NSABP Foundation Inc
Network
Eligibility
18 Years and older · Female only
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
30
States / cities
Loma Linda, California • San Diego, California • Denver, Colorado + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Early Phase 1 Interventional Results available

Nicotinamide Riboside in LVAD Recipients

NCT03727646
View directory record Official record
Conditions
Heart Failure，Congestive, Heart Failure New York Heart Association Class IV, Mitochondrial Alteration
Interventions
Nicotinamide riboside
Dietary Supplement
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 75 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Extinction Updating in Reconsolidation

NCT02154685
View directory record Official record
Conditions
Nicotine Addiction, Smoking Cessation
Interventions
Retrieval-Extinction, Non-Retrieval Extinction
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

ACEs, SIRT1, and Premature Vascular Aging in Humans

NCT07073352
View directory record Official record
Conditions
Adverse Childhood Experiences, Endothelial Dysfunction
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
2
States / cities
Iowa City, Iowa • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Phase 3 Interventional Results available

Study to Demonstrate the Efficacy, Safety and Tolerability of an Intravenous Regimen of Secukinumab Compared to Placebo in Subjects With Active axSpA

NCT04156620
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Secukinumab, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
25
States / cities
Irvine, California • La Mesa, California • San Leandro, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 18, 2024 · Synced Oct 20, 2026, 5:38 PM EDT
Recruiting Not applicable Interventional

Effect of Nicotinamide Riboside on Ketosis, Fat Oxidation & Metabolic Rate

NCT06044935
View directory record Official record
Conditions
Overweight, Obesity
Interventions
Standard Diet, Ketogenic Diet, Placebo, Nicotinamide Riboside
Other · Dietary Supplement
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 18, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Vitamin B3 Derivative Nicotinamide Riboside (NR) in Bone, Skeletal Muscle and Metabolic Functions in Aging

NCT03818802
View directory record Official record
Conditions
Healthy Elderly Volunteers
Interventions
Nicotinamide Riboside, Placebo
Dietary Supplement
Lead sponsor
Mayo Clinic
Other
Eligibility
65 Years to 80 Years · Female only
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Oct 20, 2026, 5:38 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

IV Administration of ChromaDex's Niagen® as Compared to NAD+

NCT06382688
View directory record Official record
Conditions
Healthy Aging
Interventions
NAD+ (nicotinamide adenine dinucleotide) IV, Niagen® (nicotinamide riboside) IV, Niagen® (nicotinamide riboside) oral, Placebo
Dietary Supplement · Other
Lead sponsor
Nutraceuticals Research Institute
Other
Eligibility
40 Years and older
Enrollment
53 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Franklin, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 20, 2026, 5:38 PM EDT
Completed No phase listed Observational

A Biospecimen Collection Study to Identify the Targets of Disease-Reactive T Cells in Patients With Autoimmune Disease

NCT06587828
View directory record Official record
Conditions
Autoimmune Diseases, Ulcerative Colitis, Multiple Sclerosis, Scleroderma, Ankylosing Spondylitis, Celiac Disease, Non-radiographic Axial Spondyloarthritis (Nr-axSpA), Crohn&Amp;#39;s Disease, Birdshot Chorioretinitis
Interventions
Companion blood samples with procedure
Procedure
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
11
States / cities
Orange, California • Sherman Oaks, California • Skokie, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 20, 2026, 5:38 PM EDT
Completed Not applicable Interventional

Unlocking Movement Potential: Enhancing Parkinson's Disease Treatment With Robotic EksoSkeleton

NCT06225830
View directory record Official record
Conditions
Parkinson Disease
Interventions
Eksobionics Eksoskeleton NR
Device
Lead sponsor
Albert Einstein Healthcare Network
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Elkins Park, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 20, 2026, 5:38 PM EDT